Approved PTEN IHC Companion Diagnostic for Prostate Cancer
Labcorp said it has nationwide availability of Roche’s Ventana PTEN (SP218) RxDx immunohistochemistry companion diagnostic, FDA approved to detect PTEN protein loss in prostate adenocarcinoma. The result helps identify patients eligible for AstraZeneca’s TRUQAP (capivasertib) plus abiraterone acetate and prednisone. Labcorp says it supports personalized treatment decisions via its lab network.
How this was made
The 30-second read
Why it matters
FDA approval plus nationwide availability can improve patient access to biomarker testing, potentially increasing Labcorp’s companion diagnostic test volumes and strengthening its oncology testing platform.
Market read
This is a commercialization update tied to an FDA-approved companion diagnostic, which can affect near-term expectations for Labcorp’s CDx testing demand.
What to watch
Adoption depends on clinician ordering behavior, payer coverage, and whether TRUQAP combination use expands materially; those drivers are not quantified here.
Background
The Ventana PTEN (SP218) RxDx assay is an immunohistochemistry test intended to identify PTEN protein loss in prostate adenocarcinoma to determine eligibility for capivasertib (TRUQAP) combination therapy.
Ticker impact
Labcorp announced nationwide availability of the FDA-approved Ventana PTEN (SP218) RxDx companion diagnostic through its lab network.
Near-term sentiment positive for LH tied to incremental diagnostic volume expectations; magnitude likely modest without financial figures.
The article is a product availability and commercialization update for Labcorp, but it provides no revenue, volume, or guidance impact.
Market effects
Supports continued adoption of companion diagnostics in prostate cancer and may lift sentiment around CDx testing providers.
US-focused rollout via Labcorp’s national laboratory network.
Moderate, as the approval and commercialization are US-specific but can influence broader CDx adoption narratives.
Counterpoint
Without disclosed commercial traction metrics, the market may treat this as incremental rather than earnings-moving.
Key entities
- companyLabcorp
Announced nationwide availability of the FDA-approved Ventana PTEN (SP218) RxDx assay through its lab network.
- diagnosticRoche Ventana PTEN (SP218) RxDx Assay
FDA-approved immunohistochemistry companion diagnostic for PTEN protein loss in prostate adenocarcinoma.
- drugAstraZeneca TRUQAP (capivasertib)
Treatment eligibility is linked to PTEN protein loss identified by the assay.
